Refractory warts: topical or intralesional cidofovir options

Published Date: 02 Mar 2023

New research suggests that cidofovir may be a helpful option for tender joints or joints.

Read Full News

Latest News

Do Diet Trends Improve Health? A Clinical Take

Learn which diet trends have scientific support — clean eating, detox, glow food and plant-based diets influence health differently and require individualized clinical counseling.

Exclusive-Child Vaccination Rate Drops Sharply in Michigan as RFK Jr Influences Policy

Vaccination rates among young children in Michigan dropped sharply during the first year of the Trump administration, a Reuters analysis of state data shows, providing an...

FDA Approves Icotrokinra for Moderate-to-Severe Psoriasis

This is the first IL-23 receptor-targeted oral peptide pill, and it is also being evaluated as a treatment for psoriatic arthritis, ulcerative colitis, and Crohn’s disease.

Lutikizumab Offers Relief for Refractory HS

Lutikizumab improves clinical responses and pain outcomes in patients with hidradenitis suppurativa after anti-TNF failure in a phase 2 study.

Novo Nordisk Patent Expiry Opens Door to Cheaper Weight-Loss Drugs in India

India’s diabetes and weight-loss drug market faces a shake-up as Novo Nordisk’s semaglutide patent expires, opening the door to cheaper generics.

FDA OKs Linerixibat for Cholestatic Pruritus

The oral ileal bile acid transporter inhibitor significantly and rapidly reduced cholestatic pruritus in patients with PBC in the phase 3 GLISTEN trial.

Todays Updates

Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer

In a new trial, patients with PD-L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.

FDA OKs Upfront Nivolumab+Chemo for Classic Hodgkin Lymphoma

The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.

Todays Updates

Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer

In a new trial, patients with PD-L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.

FDA OKs Upfront Nivolumab+Chemo for Classic Hodgkin Lymphoma

The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.

Latest News

Learn which diet trends have scientific support — clean eating, detox, glow food and plant-based diets influence health differently and require individualized clinical counseling.

Vaccination rates among young children in Michigan dropped sharply during the first year of the Trump administration, a Reuters analysis of state data shows, providing an...

This is the first IL-23 receptor-targeted oral peptide pill, and it is also being evaluated as a treatment for psoriatic arthritis, ulcerative colitis, and Crohn’s disease.

Lutikizumab improves clinical responses and pain outcomes in patients with hidradenitis suppurativa after anti-TNF failure in a phase 2 study.

India’s diabetes and weight-loss drug market faces a shake-up as Novo Nordisk’s semaglutide patent expires, opening the door to cheaper generics.

The oral ileal bile acid transporter inhibitor significantly and rapidly reduced cholestatic pruritus in patients with PBC in the phase 3 GLISTEN trial.

News All Time

Meta-analysis: Dermoscopic Features Distinguish ALM

Parallel ridge and multicomponent patterns are the most common dermoscopic features that identify acral lentiginous melanoma, according to a meta-analysis.

Geriatric Oncology Has Become Personalized: Here’s Why

As immunotherapy reshaped cancer care, geriatric oncology shifted toward personalized, geriatric assessment-guided treatment that prioritizes function, safety, and what matters most to older adults.

Hidradenitis Suppurativa Raises Risk for Self-Harm, Suicide

Patients with hidradenitis suppurativa have a higher risk for self-harm and suicide than matched control individuals, according to the results of a Danish cohort study.

Perianal Abscess Tied to Crohn's Disease Risk in Older Kids

Older children with perianal abscess or fistula-in-ano, especially those with recurrent perianal abscess or fistula-in-ano or gastrointestinal symptoms, are more likely to develop Crohn's disease.

Bimekizumab Not Tied to Mental Health Risk, Study Suggests

A study suggests that bimekizumab does not increase the risk for depression or suicidal ideation compared with IL-23 inhibitors in adults with psoriasis.

Should Biology Replace Organ Labels in Cancer Treatment?

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

PIP Matches PrEP for Low-Risk HIV

The use of medicine at home offers convenience and curbs costs.

Can Physical Activity Improve Skin Cancer Outcomes?

Physical activity is associated with a reduced risk for all-cause mortality and improved survival in patients with skin cancer, a meta-analysis shows.

Healthy Diet May Cut Cancer Survivors’ Premature Aging Risk

A recent study found reduced premature aging among childhood cancer survivors that adhered to established dietary guidelines.

AI Tools Helpful With Prior Auth Letters, Handouts, and More

‘Specify everything you need, do it as if you’re talking to your medical assistant,’ one dermatologist recommends.

Study Identifies Factors Linked to Early Melanoma Recurrence

Several clinicopathologic features beyond tumor thickness and ulceration are associated with recurrence risk in patients with localized stage I-II melanoma.

Antimalarials May Cut RA and SLE Hospital Admissions, Stays

Patients with RA or SLE who adhere to antimalarial therapy have a lower risk for hospital admission and fewer days of hospital stay than their nonadherent peers.

Can Fecal Transplants Enhance Immunotherapy? New Evidence

Fecal microbiota transplants may enhance patients’ response to immunotherapy, but experts caution that the latest data remain proof-of-concept and far from practice-changing.

Expert Meeting on US Measles Elimination Status Delayed to November

A meeting of an international panel of experts that was set to review the United States' measles ⁠elimination status next month has been postponed until November, the Pan...